Seychelles Medical
Commercial House, Eden Island
Mahe, Seychelles
https://seychellesmedicalservices.com
Mobile: +248 4366999

MOLECULAR DIAGNOSIS REPORT
RAPID ANTIGEN TESTING FOR SARS-COV-2 VIRUS RNA

PATIENT SURNAME / GIVEN NAME(S)

RACHEL JUDE

GENDER	DATE OF BIRTH	DOCUMENT TYPE / DOCUMENT NUMBER
Male	**1988-05-14**	**Passport / *2345**

SAMPLE COLLECTION DATE & TIME
2023-05-30 02:02:00

SAMPLE TYPE
Nasopharyngeal Swab

SAMPLE REFERENCE NO
1234

INTERPRETATION / FINAL FINDINGS

NEGATIVE FINDINGS FOR
RAPID ANTIGEN SARS-COV-2 VIRUS RNA

PROCEDURE
Detection of SARS-CoV2 Viral RNA performed on Real Time Polymerase Chain Reaction (RT-PCR). RNA is extracted by using abGenix RNA/DNA extractor system. Amplification of extracted RNA was performed by Macurra SARS-Cov-2 fluorescent PCR Kit by using abGenixQ Real-Time PCR system. Positive and negative controls are included in each run to confirm validity and accuracy of the test.

INTERPRETATION
This assay does qualitative detection for SARS-CoV2 Virus that covers three genes (E-Gene, N-Gene & ORF1ab)
Both positive and negative controls for the tested virus showed expected result.
Not detected results may not always rule out current or future infection. Please correlate with clinical findings and repeat if necessary. Positive result indicates the RNA from SARS-CoV2 was detected and patient is infected
Negative result indicates SARS-Cov2-Virus not present in specimen above the limit of detection

LIMITATIONS
The detection of viral RNA is dependent on the viral load in the specimen representing an acute infection, that is early in the disease. Pre-analytical variables (i.e. specimen quality, handling/transport conditions) may also adversely affect the results & analytical variables perhaps Virus mutation. The performance characteristics of this test has been validated in the molecular virology diagnostic unit of the Seychelles Medical Services, and is continuously monitored as part of quality assurance procedures, including enrolment with local Head

REPORT DATE	PERFORMED	APPROVED
May 30, 2023	**Lead Analyst - Rehmat** HPC21/0791	**Consultant - S. Raza** HPC20/0737